PRKDC and cancer: Although some promising preclinical and early-phase clinical results have been reported recently (9,11,12), the precise management of DNA-PK-targeted therapy remains a challenge due to the limited knowledge on the physiological functions of DNA-PK and lack of biomarkers that predict the efficacy of DNA-PK inhibitors in cancer treatment.